Evaluation of fidaxomicin use in community hospitals after a clinical guideline change at a large health system and opportunities for stewardship
After updating our health system's Clostridioides difficile treatment protocols in 2018, we reviewed 104 unique hospital encounters involving fidaxomicin at 10 community hospitals. Half (50%) of regimens were adherent to our guidelines, with infectious diseases (ID) providers were frequently nonadhe …
Nice @StanfordHealth study sharing experience discharging 15 patients on fidaxomicin for #CDiff - 80% had co-pays of $35 or less, 73% did not require prior authorization, and 30 day recurrence rate was 7% (1 out if 15). Does this match your experience?
Nice @StanfordHealth study sharing experience discharging 15 patients on fidaxomicin for #CDiff - 80% had co-pays of $35 or less, 73% did not require prior authorization, and 30 day recurrence rate was 7% (1 out if 15). Does this match your experience? https://t.co/6GePeWM2M6— Michael Calderwood, MD, MPH (@CalderwoodMD) January 22, 2022
Effect of Doxycycline in Decreasing the Severity of Clostridioides difficile Infection in Mice
Background: Doxycycline possesses antibacterial activity against Clostridioides difficile and anti-inflammatory effects. Materials and Methods: The influence of doxycycline on the development of CDI was studied in an established animal model of CDI using C57BL/6 mice. Results …
Inhibition of Clostridioides difficile Toxins TcdA and TcdB by Ambroxol
Clostridioides (C.) difficile produces the exotoxins TcdA and TcdB, which are the predominant virulence factors causing C. difficile associated disease (CDAD). TcdA and TcdB bind to target cells and are internalized via receptor-mediated endocytosis. Translocation of the toxins' enzyme …
Should fidaxomicin be the preferred treatment for C. difficile ? - Healio
Infectious Disease News | New guidelines issued in 2021 stated a preference for fidaxomicin as first-line treatment for Clostridioides difficile infection, despite concerns about its cost. We asked Infectious Disease News Editorial Board Member Jeff Brock, PharmD, MBA, BCPS-AQ ID, an infectious disease pharmacy specialist at Mercy Medical Center in Des Moines, Iowa, if the new guidelines got it right.
In this phase 3 RCT, the percentage of pts with recurrent #Cdiff was 12% in the SER-109 group and 40% in the placebo group (RR: 0.32; 95% CI: 0.18 to 0.58; P0.001) Congratulations @DrPaulGastro !
In this phase 3 RCT, the percentage of pts with recurrent #Cdiff was 12% in the SER-109 group and 40% in the placebo group (RR: 0.32; 95% CI: 0.18 to 0.58; P
Macayla Peterson - Peggy Lillis Foundation
Nine months ago my world was turned upside down. I was prescribed an antibiotic for a wisdom tooth procedure. Five days later I woke up to the worst pain of my life. After two days of pure misery crying on my bathroom floor, I went into urgent care. The doctor …
Jane Freeman on Twitter
Interesting. Important to note ⬆️ vanc levels in human faeces are in xs of MICs. Ribotyping would answer whether expansion of single ribotype or more. @HCAILeeds and @SmitsLab optimising #Cdiff susceptibility testing methods in @ESCMID sponsored project. @EUCAST_EUCAST— Jane Freeman (@drjanefreeman) January 15, 2022
Oral vancomycin for clostridioides difficile prophylaxis in allogenic hematopoietic cell transplant
Background Neutropenia and antibiotic use put patients at risk for Clostridioides difficile infection (CDI) following allogenic hematopoietic cell transplant (alloHCT). CDI following alloHCT has bee...
Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin
C. difficile strains exhibiting reduced susceptibility to vancomycin are currently circulating in patient populations. The spread of strains resistance to vancomycin, a first-line antibiotic for CDI, poses a serious therapeutic challenge. Routine susceptibility testing may be necessary.
Oral vancomycin for clostridioides difficile prophylaxis in allogenic hematopoietic cell transplant
Oral vancomycin was associated with reduced CDI incidence in patients that underwent an alloHCT without negatively affecting post-transplant outcomes. The contribution of confounders cannot be excluded. This article is protected by copyright. All rights reserved.
Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis
The anaerobic, gastrointestinal pathogen Clostridioides difficile can cause severe forms of enterocolitis which is mainly mediated by the toxins it produces. The RNA polymerase inhibitor Fidaxomicin is the current gold standard for the therapy of C. difficile infections due to several beneficial fea …
The role of the microbiota in the management of intensive care patients
The composition of the gut microbiota is highly dynamic and changes according to various conditions. The gut microbiota mainly includes difficult-to-cultivate anaerobic bacteria, hence knowledge about its composition has significantly arisen from culture-independent methods based on next-generation …
Successful fidaxomicin hospital discharges of adult patients with Clostridioides difficile infections post 2021 guidelines - are economic barriers finally coming down?
We reviewed C.difficile positive patients discharged on fidaxomicin after local adoption of 2021C.difficile infection (CDI) guidelines. From June 14 - Oct 3, 2021, 80% (12/15) had copayments $0-$35, and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.